In COVID-19 clinical update #71, Daniel Griffin reviews updated school and child care guidance from CDC, transmission in schools, accuracy of lateral flow assays, update to J&J/Janssen vaccine EUA to include GBS, interim immunogenicity of Ad.26.CoV2.s, effectiveness of mRNA vaccines to prevent hospitalization, Bamlanivimab plus Etesevimab for mild or moderate disease, and a meta-analysis of ivermectin results.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• School and child care guidance (CDC)
• Transmission in schools (CDC)
• Accuracy of lateral flow diagnostics (Lancet)
• GBS with Ad.26.CoV2.s vaccine (FDA)
• Ad.26.CoV2.s interim immunogenicity (NEJM)
• mRNA vaccine effectiveness to prevent hospitalization (medRxiv)
• Bamlanivimab plus Etesevimab (NEJM)
• Meta-analysis of ivermectin studies (Clin Inf Dis)
• Letters read on TWiV 780
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]